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Abstract The majority of patients presenting with a first
clinical symptom suggestive of multiple sclerosis (MS) do
not fulfill the MRI criteria for dissemination in space and
time according to the 2010 revision of the McDonald
diagnostic criteria for MS and are thus classified as clini-
cally isolated syndrome (CIS). To re-evaluate the utility of
cerebrospinal fluid (CSF) analysis in the context of the
revised McDonald criteria from 2010, we conducted a
retrospective multicenter study aimed at determining the
prevalence and predictive value of oligoclonal IgG bands
(OCBs) in patients with CIS. Patients were recruited from
ten specialized MS centers in Germany and Austria. We
collected data from 406 patients; at disease onset, 44/406
(11 %) fulfilled the McDonald 2010 criteria for MS.
Intrathecal IgG OCBs were detected in 310/362 (86 %) of
CIS patients. Those patients were twice as likely to convert
to MS according to McDonald 2010 criteria as OCB-neg-
ative individuals (hazard ratio = 2.1, p = 0.0014) and in a
shorter time period of 25 months (95 % CI 21–34) com-
pared to 47 months in OCB-negative individuals (95 % CI
36–85). In patients without brain lesions at first attack and
presence of intrathecal OCBs (30/44), conversion rate to
MS was 60 % (18/30), whereas it was only 21 % (3/14) inU. K. Zettl and H. Tumani contributed equally to this work.
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those without OCBs. Our data confirm that in patients with
CIS the risk of conversion to MS substantially increases if
OCBs are present at onset. CSF analysis definitely helps to
evaluate the prognosis in patients who do not have MS
according to the revised McDonald criteria.
Keywords OCB  CSF  Multiple sclerosis  Biomarker
Introduction
Multiple sclerosis (MS) is a chronic inflammatory disease
mainly characterized by demyelination and axonal loss [1].
A formal diagnosis of MS is based on clinical and radio-
logical findings with an increasing role ofMRI examinations
as established in the 2010 revision of the so-calledMcDonald
diagnostic criteria [2]. Here, cerebrospinal fluid (CSF)
analysis, and in particular the detection of intrathecal IgG
oligoclonal bands (OCBs), is a supportive criterion for a
diagnosis of primary progressive multiple sclerosis (PPMS)
but not in the more common relapsing–remitting form
(RRMS) [2]. Nevertheless, the importance of OCBs, espe-
cially in the context of differential diagnosis and misdiag-
nosis in MS, is shown in several studies [3–7]. Most often,
the disease starts with a single clinical attackwhich is termed
clinically isolated syndrome (CIS) when the MRI criteria of
dissemination in space and time are not fulfilled [1, 8].
Several biomarkers allowing the prediction of conversion
from CIS to clinically definite multiple sclerosis (CDMS)
have been suggested [9–13]: Besides cerebrospinal
demyelinating MRI lesions, especially OCBs restricted to
the CSF of CIS patients are associated with a higher risk for
conversion to CDMS independent of the baseline MRI
results [14, 15]. Additionally, positive OCB predicts CDMS
in children with optic neuritis [16]. However, most of these
CSF studies were conducted in the context of previous
diagnostic criteria, i.e., McDonald criteria 2005.
In this study, we aimed to evaluate the prevalence and
predictive value of OCBs in the context of the revised
McDonald criteria 2010 [2] and therefore retrospectively
analyzed 406 patients with a first presentation suggestive of
MS from ten centers in Germany and Austria. We compared
MRI and OCB findings as well as the disease course and
conversion toMS according toMcDonald 2010 criteria over
a follow-up time of up to 12 years (median 32 months).
Materials and methods
Participants and inclusion criteria
In total, 406 patients with a first manifestation suggestive
of MS and for whom sufficient baseline CSF and MRI data
were available as well as clinical and radiological follow-
up were included. MRI data were considered sufficient if
theses enabled to classify according to the Swanton criteria
for dissemination in space [17], Montalban criteria for
dissemination in time [18] and the revised McDonald 2010
criteria for RRMS [2]. CIS was defined as a first clinical
event suggestive of MS not yet meeting the revised
McDonald 2010 criteria for RRMS. Patients were included
irrespective of the number of T2 hyperintense lesions on
cerebral MRI at baseline, i.e., also patients without T2
hyperintense lesions on cerebral MRI were included in the
study. Patients who already fulfilled the revised McDonald
criteria 2010 for a diagnosis of MS were not taken into
account for the evaluation of predictive factors (MRI and
OCB findings) concerning conversion to definite MS
according to McDonald 2010 criteria.
CSF and serum samples were analyzed for routine
workup in the local centers according to international
recommendations on standards for CSF analysis [19].
Data collection
The diagnostic workup, including MRI, CSF and clinical
assessment, was performed in each participating center.
Data were collected retrospectively with the help of an
Excel spreadsheet. The number and localization of T2 and
gadolinium-enhancing (GD?) lesions on MRIs were
evaluated at each participating center. Detection of
intrathecal immunoglobulin (IgG) OCBs was performed
using isoelectric focusing followed by immunoblotting,
immunofixation or rarely silver staining. Additional CSF
data like leukocyte count, albumin CSF-to-serum quotient
(QAlb), IgG CSF-to-serum quotient (QIgG) and demo-
graphic data were provided by each center.
Statistical analyses
Absolute and relative frequencies are given for discrete
variables, and median and interquartile range for continuous
variables. Differences between CIS–CIS and CIS-MS were
analyzed by Chi Square test or Mann–Whitney U test on a
univariate basis in an exploratory sense. Kaplan–Meier
surviving analysis was performed to assess conversion to
definite MS and hazard ratios were calculated by Cox pro-
portional hazard model. p values below 0.05 were consid-
ered to be significant. Sensitivity was calculated as (true
positive/[true positive ? false negative]), and specificity
was calculated as (true negative/[true negative ? false
positive]). The positive predictive value (PPV) was calcu-
lated as (true positive/[true positive ? false positive]), and
the negative predictive value (NPV) as (true negative/[true
negative ? false negative]). For all diagnostic values, the
exact 95 % confidence intervals were given.
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Results
We collected data from 406 patients, 277 (68 %) of whom
were female. The mean age at clinical onset was 37 years
(SD ± 12). At disease onset, 44/406 (11 %) patients ful-
filled the McDonald 2010 criteria for MS [2], 137/406
(34 %) the Swanton criteria (dissemination in space) [17],
87/406 (21 %) the Montalban (dissemination in time) cri-
teria [18], and 44/406 (11 %) had no brain lesions.
Intrathecal IgG OCBs were detected in 351/406 (86 %) and
in 310/362 (86 %) CIS patients. 229/310 (74 %) converted
to MS clinically or on MRI according to the McDonald
2010 criteria during the follow-up period of up to
154 months (median 32 months). All patient characteris-
tics, as well as MRI and OCB findings, are summarized in
Table 1 and Fig. 1.
While the conversion rate (by clinical or MRI signs) in
CIS patients showing intrathecal OCBs (310/362) was
74 % (229/310), it was 44 % (23/52) in those CIS patients
with negative OCBs. In patients without brain lesions at
first attack and presence of intrathecal OCBs (30/44),
conversion rate to MS was 60 % (18/30), whereas it was
only 21 % (3/14) in those without OCBs (Fig. 1), revealing
a positive predictive value of 79 % and a likelihood ratio
for conversion of 3.4 in this subset of patients.
The median conversion time to definite MS for CIS
patients with positive OCBs was 25 months (95 % CI
21–34) compared to 47 months (95 % CI 36–85) in those
patients without OCBs (Fig. 2). CIS patients with
intrathecal OCBs were twice as likely to convert to definite
MS as OCB-negative individuals (hazard ratio = 2.1,
p = 0.0014).
In Table 2, sensitivity, specificity, positive (PPV) and
negative (NPV) predictive values of MRI and CSF
parameters concerning conversion from CIS to definite MS
are summarized. Whereas OCBs show the highest sensi-
tivity of 91 % and an NPV of 39 %, Montalban criteria and
OCB yield the highest specificity of 95 % (same result is
achieved with Montalban criteria alone) and Montalban
criteria reveal the best PPV of 92 %.
Among the 44 MS patients satisfying the McDonald
2010 criteria at disease onset, follow-up disease activity
(by clinical or MRI signs) was observed in 36 out of those
41 who were OCB positive (88 %), whereas only one of
the three patients without OCBs developed a second clin-
ical attack detected by clinical or MRI signs (Fig. 1).
Discussion
The last revision of the McDonald diagnostic criteria for
MS, dating from 2010, does not include CSF criteria for a
diagnosis of RRMS, while OCBs may support a diagnosis
of PPMS [2]. Nevertheless, studies according to the pre-
vious diagnostic criteria showed that OCB positivity in CIS
patients is a predictor for conversion to CDMS in adults
[11, 15, 20] and children [16] independent of other factors
[15, 21]. We now investigated the prevalence and predic-
tive value of OCBs in the revised McDonald criteria 2010
era. Only 11 % of our patients with a first manifestation
suggestive of MS met the revised McDonald criteria at
disease onset. Thus, for the majority of CIS patients, fur-
ther information allowing estimating the risk to develop
definite MS would be of (high) value. We found OCB
positivity in 86 % of 362 CIS patients at clinical onset.
Those patients were approximately twice as likely to con-
vert to definite MS and within a shorter period of time as
OCB-negative CIS patients. This is in concordance with
results in other cohorts, mostly referring to the revised
McDonald criteria 2005 [11, 15, 21]. Whereas MRI criteria
Table 1 Overview on
demographics and clinical data
All patients
(n = 406)
CIS patients (n = 362) p values CIS patients
OCB pos. vs. neg.
OCB positive
(n = 310)
OCB negative
(n = 52)
Age (years) 36 (27–46) 36 (27–46) 39 (28–44) 0.59
Females 277 (68 %) 215 (69 %) 31 (60 %) 0.16
Follow-up (months) 32 (15–50) 33 (16–50) 24 (13–48) 0.16
McDonald 2010 44 (11 %) – – –
Swanton 137 (34 %) 82 (26 %) 11 (21 %) 0.42
Montalban 87 (21 %) 35 (11 %) 8 (15 %) 0.40
Conversion to definite MS – 229 (74 %) 23 (44 %) \0.0001
Cell count (n/ll) 6 (3–12) 6 (3–12) 2 (1–3) \0.0001
OCB positive 351 (86 %) 310 (86 %) –
Numbers are medians (interquartile range, IQR) or n (%)
CIS clinically isolated syndrome; MS multiple sclerosis (according to McDonald 2010 criteria); OCB
oligoclonal band
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(Barkhof, Swanton, and Montalban) showed a higher
specificity, OCBs performed best concerning sensitivity
and NPV. Combining MRI criteria and OCB did not add to
sensitivity or specificity for the prediction of conversion to
definite MS compared to MRI criteria alone, despite that
both MRI and the presence of OCBs in CSF have been
repeatedly shown to be independent predictive factors
[15, 21]. In another subset of patients, i.e., those who do
not show any brain lesions (11 % of all patients), OCB-
positive individuals are three times more likely to develop
definite MS than OCB-negative patients; hence OCBs are
the only predictor of conversion in this subset of CIS
patients.
Our data further underline the utility and importance of
CSF diagnostics, especially the detection of OCBs. We
thus continue to recommend the inclusion of OCBs in the
diagnostic workup of patients under the differential
Fig. 1 MRI (according to the revised McDonald criteria 2010) and
OCB characteristics of all CIS patients. MS multiple sclerosis, MRI
magnetic resonance imaging, OCB oligoclonal bands, CIS clinically
isolated syndrome, Progression follow-up disease activity by clinical
or MRI signs, Conversion fulfillment of the revised McDonald criteria
2010 in the follow-up time, n.d. not determined
Fig. 2 Kaplan–Meier survival curves for OCB-positive (red) and -
negative (blue) CIS patients concerning the time of conversion to
definite multiple sclerosis according to McDonald 2010 criteria.
Patients who did not convert to definite MS and/or whose follow-up
time was less than 24 months were censored (OCB pos. = 62, OCB
neg. = 19, indicated by dash on the curve). The numbers of subjects
at risk are given in the table under the graph
Table 2 Sensitivity, specificity, positive (PPV) and negative (NPV)
predictive values in percent (95 % confidence intervals) for CSF and
MRI parameters regarding conversion of clinically isolated syndrome
to definite multiple sclerosis
Parameter Sensitivity Specificity PPV NPV
Barkhof 24 (18.5–29.9) 80 (70.4–90.3) 81 23
Swanton 27 (21.5–33.3) 79 (69.9–89.2) 82 24
Montalban 15 (10.3–19.8) 95 (89.8–100) 92 24
cell count ([4/ll) 58 (51.3–64.5) 55 (42.4–67.2) 82 27
OCB 91 (87.1–94.7) 21 (10.8–31.1) 80 39
Cell count and OCB 57 (50.3–63.5) 58 (45.8–70.3) 83 28
Barkhof and OCB 21 (16.0–26.9) 82 (72.7–91.8) 81 23
Swanton and OCB 24 (18.1–29.4) 81 (70.8–90.5) 81 23
Montalban and
OCB
13 (8.8–17.7) 95 (89.8–100) 91 24
Values are given for the comparison between the absence or presence
of the regarding condition (e.g., OCBs-positive subjects compared to
OCB-negative). Follow-up for non-converters had to be at least
24 months
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diagnosis of an MS [3]. CIS patients showing a positive
OCB finding are at a higher risk of developing a definite
MS; particularly in CIS patients not showing lesions, OCBs
are of great interest. This might be helpful for the clinician
to decide whether or not a disease-modifying
immunotherapy should be started.
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